Related references
Note: Only part of the references are listed.A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
Edward Chu
CLINICAL COLORECTAL CANCER (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunotherapy earns its spot in the ranks of cancer therapy
Drew Pardoll et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Maintenance Therapy for First-Line Metastatic Colorectal Cancer: Activity and Sustainability
John H. Strickler et al.
ONCOLOGIST (2012)
Sipuleucel-T for the Treatment of Advanced Prostate Cancer
Mark W. Frohlich
SEMINARS IN ONCOLOGY (2012)
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Assessing oncologic benefit in clinical trials of immunotherapy agents
R. K. Hales et al.
ANNALS OF ONCOLOGY (2010)
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
Ki Y. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Understanding the Predictive Role of K-ras for Epidermal Growth Factor Receptor-Targeted Therapies in Colorectal Cancer
Francisco Javier Ramos et al.
CLINICAL COLORECTAL CANCER (2008)
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler et al.
NATURE MEDICINE (2007)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape
M Schmidt et al.
ALLERGY (2006)
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
MR Weihrauch et al.
CLINICAL CANCER RESEARCH (2005)
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma:: increased interferon-α/β-inducible gene expression, without significant toxicity
JW Friedberg et al.
BLOOD (2005)
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells:: A first clinical phase I/II trial
B Wittig et al.
HUMAN GENE THERAPY (2001)
Share Paper
